Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
advances in neurology
adverse drug reaction
algorithm
analgesic
atogepant
calcitonin gene related peptide
calcitonin gene-related peptide receptor blocker
CAT scan
children
cluster headache
complications
controversies in neurology
cost
dementia, autoimmune
diagnostic criteria
efficacy
eletriptan
epidemiology of neurology
eptinezumab
erenumab
fremanezumab
galcanezumab
headache
headache, preventive treatment
headache, recurrent
migraine
migraine, children
migraine, chronic
migraine, intractable
migraine, pathogenesis
migraine, prophylaxis
migraine, treatment of
monoclonal antibodies
narcotic analgesics
neurologic disease, diagnoses of
nonsteroidal anti-inflammatory drug
prevention of neurologic disorders
quality of life
recurrent
review article
rimegepant
safety
serotonin agonist
serotonin antagonist
sumatriptan
telcagepant
topiramate
treatment of neurologic disorder
treatment resistant
trigeminovascular system
triptans
ubrogepant
Showing articles 0 to 50 of 1232 Next >>

Calcitonin Gene-Related Peptide-Targeted Therapy in Migraine: Current Role and Future Perspectives
Lancet 405:1014-1026, Versijpt,J.,et al, 2025

New Treatments for Migraine: CGRP Monoclonal Antibodies, Gepants, and Ditans
BMJ 390:e085564, Burch, R. & Rittenberg, E., 2025

Comparative Effects of Drug Interventions for the Acute Management of Migraine Episodes in Adults:Systematic Review and Network Meta-Analysis
BMJ 386:e080107, Karlsson,W.K.,et al, 2024

Atogepant for the Preventive Treatment of Chronic Migraine (PROGRESS): A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial
Lancet 402:775-785, Pozo-Rosich,P.,et al, 2023

Acute Treatment for Migraine
JAMA 325:2346-2347, Burch, R. & Rayhill, M., 2021

Atogepant for the Preventive Treatment of Migraine
NEJM 385:695-706, Ailani,J.,et al, 2021

One-Year Sustained Efficacy of Erenumab in Episodic Migraine
Neurol 95:e469-e479, Goadsby, P.J.,et al, 2020

Migraine
NEJM 383:1866-1876, Ashina, M., 2020

Remigepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine
NEJM 381:142-149, Lipton, R.B.,et al, 2019

Trial of Galcanezumab in Prevention of Episodic Cluster Headache
NEJM 381:132-141, Goadsby, P.J.,et al, 2019

Targeting Calcitonin Gene-Related Peptide: A New Era in Migraine Therapy
Lancet 394:1765-1774, Charles, A. & Pozo-Rosich, P., 2019

Ubrogepant for the Treatment of Migraine
NEJM 381:2230-2241, Dodick, D.W.,et al, 2019

Erenumab in Chronic Migraine
Neurol 92:e2250-e2260, Lipton, R.B.,et al, 2019

Preventive Migraine Drug Approved
JAMA 320:1746, , 2018

Efficacy and Tolerability of Erenumab in Patients with Episodic Migraine in Whom Two-of-Four Previous Preventive Treatments were Unsuccessful: A Randomised, Double-Blind, Placebo-Controlled, Phase 3b Study
Lancet 392:2280-2287,2241, Reuter, U.,et al, 2018

Galcanezumab in Chronic Migraine
Neurol 91:e2211-e2221, Detke, H.C.,et al, 2018

New Drugs in Migraine Treatment and Prophylaxis: Telcagepant and Topiramate
Lancet 376:645-655, Edvinsson,L. &Linde,M., 2010

Diagnosis and Management of Migraine
BMJ 312:1279-1283, Goadsby,P.J.&Olesen,J., 1996

Efficacy and Safety of Ofatumumab Treatment for Anti-NMDA Receptor Autoimmune Encephalitis (OFF-AE): A Prospective, Multicenter Cohort Study
Ann Neurol 98:80-92, Guo,K.,et al, 2025

Clinicopathologic conference, Malignant Mixed Germ-Cell Tumor and Anti-NMDA Receptor Encephalitis
NEJM 303:488-496, Case 22-2025, 2025

Anti-NMDAR Encephalitis Triggered by EBV and HSV-1
Medicine 104:28, Zhan,X.,et al, 2025

Neuroleptic Malignant Syndrome
NEJM 391:1130-1138, Wijdicks,E.F.M. & Ropper,A.H., 2024

Anti-NMDA Receptor Encephalitis Presenting with Cerebellitis in a Pediatric Patient
Neurol 102:e209259, Moehlman,M. & Kornbluh,A.B., 2024

Overlapping Anti-NMDAR Encephalitis and Multiple Sclerosis: A Case Report and Literature Review
Front Immunol doi:10.3389/Fimmun.2023.1088801, Liu,P.,et al, 2023

Recurrent Anti-NMDA Receptor Encephalitis After Mycoplasma Pnemonia Infection
Am J Psychiatry 180:880-883, Dickson,K.S.,et al, 2023

Anti0NMDAR Encephalitis Presenting with Unilateral Insular Diffusion Restriction on Brain Imaging: Mimicking as a Stroke
Ann Clin Case Rep 8:21515, Pawar,M.,et al, 2023

Risk of First Ischaemic Stroke and Use of Antidopaminergic Antiemetics: Nationwide Case-Time-Control Study
BMJ 376:e061921, Benard-Laribiere, A.,et al, 2022

Dura Mater Thickening and Enhancement in Anti-NMDAR Encephalitis
Neurol 99:628-629, Xia, C. & Chen, H.S., 2022

Atypical Unilateral Cortical Ribboning in Anti-NMDA Receptor Encephalitis
Neurol 99:1062-1063, Chen,A.Y.,et al, 2022

Case Report: Anti-NMDA Receptor Encephalitis with Bilateral Hearing Loss as the Initial Symptom
Front Neurol doi:10.3389/FNEUR.2021.648911, Cheng,H.,et al, 2021

Anti-NMDAR Encephalitis Presenting as Stroke-Like Episodes in Children: A Case Series from a Tertiary Care Referral Centre from Southern India
J Pediatr Neurosci 16:194-198, Gowda,V.K.,et al, 2021

Anti-NMDAR Encephalitis with Overlapping Demyelinating Syndrome
Neurol 94:e1866-e1869, Kim, H.W., et al, 2020

Clnicopathologic Conference Anti-N-Methyl-D-Aspartate (NMDA) Receptor Encephalitis
NEJM 379:870-878, CASE 27-2018, 2018

Brain MRI Characteristics of Patients with Anti-N-Methyl-D-Aspartate Receptor Encephalitis and Their Associations with 2-Year Clinical Outcome
AJNR 39:824-829, Zhang, T.,et al, 2018

Antibody-Mediated Encephalitis
NEJM 378:840-851, Dalmau, J.,et al, 2018

Autoimmune Encephalitides: A Broadening Field of Treatable Conditions
Neurologist 22:1-13, Kalman, B., 2017

Paraneoplastic and Autoimmune Encephalitis
UptoDate July, Dalmau, J.,et al, 2017

NMDA-Receptor Encephalitis
DynaMed Plus Sept 2016, Rae-Grant, A.,et al, 2016

Recognizing Autoimmune-Mediated Encephalitis in the Differential Diagnosis of Limbic Disorders
AJNR 36:2196-2205, da Rocha, A.J.,et al, 2015

Autoimmune Post-Herpes Simplex Encephalitis of Adults and Teenagers
Neurol 85:1736-1743, 1730, Armangue, T.,et al, 2015

Clinical Specificities of Adult Male Patients with NMDA Receptor Antibodies Encephalitis
Neurol 82:556-563, Viaccoz, A.,et al, 2014

Paraneoplastic Neurological Syndromes
Clin Exp Immunol 175:336-348, Leypoldt, F. & Wandinger, K.-P., 2014

Herpes Simplex Encephalitis as a Potential Cause of Anti-N-Methyl-D-Aspartate Receptor Antibody Encephalitis
JAMA Neurol 71:344-346, DeSena, A.,et al, 2014

Herpes Simplex Virus Encephalitis is a Trigger of Brain Autoimmunity
Ann Neurol 75:317-323, Armangue, T.,et al, 2014

Paediatric Autoimmune Encephalopathies: Clinical Features, Laboratory Investigations and Outcomes in Patients with or without Antibodies to known Central Nervous System Autoantigens
JNNP 84:748-755, Hacohen, Y.,et al, 2013

Late-Onset Anti-NMDA Receptor Encephalitis
Neurol 81:1058-1063, Titulaer, M.,et al, 2013

Frequency and Characteristics of Isolated Psychiatric Episodes in Anti-N-Methyl-D-Aspartate Receptor Encephalitis
JAMA Neurol 70:1133-1139, Kayser, M.S.,et al, 2013

Central Nervous System Neuronal Surface Antibody Associated Syndromes: Review and Guidelines for Recognition
JNNP 83:638-645, Zuliani,L.,et al, 2012

Autoimmune Epilepsy
Arch Neurol 69:582-593,565, Quek, A.M.L.,et al, 2012



Showing articles 0 to 50 of 1232 Next >>